Eris Lifesciences · NSE: ERIS · BSE: 540596
Q1 FY19 results · Apr–Jun 2018
Eris Lifesciences reported revenue from operations of ₹250.76 crore and net profit of ₹71.56 crore for Q1 FY19 (Apr–Jun 2018), on a consolidated basis.
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 250.76 | — | — | — | — |
| Other income | 3.52 | — | — | — | — |
| Total income | 254.28 | — | — | — | — |
| Profit before tax | 77.69 | — | — | — | — |
| Net profit for the period | 71.56 | — | — | — | — |
| Attributable to shareholders of the company | 71.25 | — | — | — | — |
| EPS, basic (₹) | 5.18 | — | — | — | — |
| Net margin (%) | 28.5 | — | — |
| Item | Q1 FY19 | Q1 FY18 | YoY | Q4 FY18 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 226.50 | — | — | — | — |
| Other income | 4.51 | — | — | — | — |
| Total income | 231.00 | — | — | — | — |
| Profit before tax | 75.42 | — | — | — | — |
| Net profit for the period | 70.10 | — | — | — | — |
| EPS, basic (₹) | 5.10 | — | — | — | — |
| Net margin (%) | 31.0 | — | — |
Consolidated
- Filed with BSE
- 10 Aug 2018, 17:37 IST
- Board meeting
- 09 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2018, 17:37 IST
- Board meeting
- 09 Aug 2018
- Period
- 01 Apr 2018 to 30 Jun 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE